Eleanor Gregson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eleanor Gregson has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Adrienn Blasko
Medical Research Council Cancer Unit, Hutchison/Medical Research Council Research Centre, University of Cambridge, Cambridge, UK
1 shared publicationAhmad Miremadi
Cambridge University Hospitals NHS Trust, Cambridge, UK
1 shared publicationAikaterini Varanou Jenkins
Medical Research Council Cancer Unit, Hutchison/Medical Research Council Research Centre, University of Cambridge, Cambridge, UK
1 shared publication- Cassandra Kosmidou
MRC Cancer Unit, Box 197, Cambridge Biomedical Campus, Cambridge, CB2 0XZ, UK
1 shared publication Dan J. Woodcock
Big Data Institute, University of Oxford, Oxford, UK
1 shared publication- David C. Wedge
Manchester Cancer Research Centre, The University of Manchester, Manchester, UK
1 shared publication
Latest Publications
- 7 September 2020
- Published by Springer Nature in Nature Medicine
- Vol. 26 (11) , 1726-1732
Genomic copy number predicts esophageal cancer years before transformation
Recent studies show that aneuploidy and driver gene mutations precede cancer diagnosis by many years1,2,3,4. We assess whether these genomic signals can be used for early detection and pre-emptive cancer treatment using the neoplastic precursor lesion Barrett’s esophagus as an exemplar5. Shallow whole-genome sequencing of 777 biopsies, sampled from 88 patients in Barrett’s esophagus surveillance over a period of up to 15 years, shows that genomic signals can distinguish progressive from stable disease even 10 years before histopathological transformation. These findings are validated on two independent cohorts of 76 and 248 patients. These methods are low-cost and applicable to standard clinical biopsy samples. Compared with current management guidelines based on histopathology and clinical presentation, genomic classification enables earlier treatment for high-risk patients as well as reduction of unnecessary treatment and monitoring for patients who are unlikely to develop cancer.
- 7 September 2020
- Published by Springer Nature in Nature Medicine
- Vol. 26 (11) , 1726-1732
Genomic copy number predicts esophageal cancer years before transformation
Recent studies show that aneuploidy and driver gene mutations precede cancer diagnosis by many years1,2,3,4. We assess whether these genomic signals can be used for early detection and pre-emptive cancer treatment using the neoplastic precursor lesion Barrett’s esophagus as an exemplar5. Shallow whole-genome sequencing of 777 biopsies, sampled from 88 patients in Barrett’s esophagus surveillance over a period of up to 15 years, shows that genomic signals can distinguish progressive from stable disease even 10 years before histopathological transformation. These findings are validated on two independent cohorts of 76 and 248 patients. These methods are low-cost and applicable to standard clinical biopsy samples. Compared with current management guidelines based on histopathology and clinical presentation, genomic classification enables earlier treatment for high-risk patients as well as reduction of unnecessary treatment and monitoring for patients who are unlikely to develop cancer.